Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
---|---|---|---|---|
Duvelisib | Copiktra | 4.5. Interactions with other medicinal products | Interactions with Cytochrome (CYP3A4) substrate | Mar,2023 |
Sodium Zirconium Cyclosilicate | Lokelma | 4.5. Interactions with other medicinal products | Interactions with tacrolimus | Mar,2023 |
Moxifloxacin | Avalox | 4.5. Interactions with other medicinal products | Interaction with agents containing bivalent or trivalent cation, charcoal, warfarin, nonsteroidal anti-inflammatory drugs , quinolone, and atenolol | Mar,2023 |
Fluoxetine | Prozac | 4.5. Interactions with other medicinal products | Interaction with Benzodiazepines, Antipsychotics, Drug that is tightly bound to protein (e.g., Coumadin, Digitoxin) and Olanzapine. | Mar,2023 |
Talazoparib Tosylate | Talzenna | 4.5. Interactions with other medicinal products | Interactions with P-gp inducer, rifampin, and rifampin | Mar,2023 |
Fentanyl | Durogesic | 4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects | Opioid use disorder (abuse , dependence and tolerance) , Drug dependence, Drug tolerance | Jan,2023 |